Conquering Antiviral Drug Resistance via Development of Novel Antivirals and New Testing Methods for Drug Resistance: From Bench to Bedside
A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 166
Special Issue Editors
Interests: hepatitis viruses; poxviruses; coronaviruses; arboviruses; enterovirus; influenza; clinical and diagnostic virology; virus-host interactions; antiviral development
Special Issues, Collections and Topics in MDPI journals
Interests: structure-based drug design, high-throughput screening, medicinal chemistry, electrophysiology, peptide chemistry, biophysics, virology
Special Issues, Collections and Topics in MDPI journals
Interests: clinical virology, molecular testing, antiviral resistance testing, HIV drug resistance testing, automation, molecular assay development
Special Issue Information
Dear Colleagues,
Acute and chronic viral infections, e.g., influenza, COVID-19, enteroviruses, viral hepatitis, HIV/AIDS, and Mpox, affect millions of people worldwide and constitute a significant global public health threat. While antivirals against medically important viruses are developed and marketed, antiviral resistance has become an important medical and public health issue due to the limited research or application of antiviral resistance testing and gaps in novel antiviral development. On one hand, similar to antibiotic resistance and its susceptibility testing with global attention, antiviral drug resistance testing warrants more research and development for public health surveillance and medical purposes. While viral load assays have some utility to monitor clinical treatment response and detect “clinical resistance” in response to antiviral treatment, more sensitive and faster molecular testing for antiviral drug resistance mutations may be a valuable tool for the screening and detection of “genotypic resistance” to predict “clinical resistance”. On the other hand, novel antiviral development is an essential and ultimate approach to treat refractory, drug-resistant viral infections. There has recently been remarkable progress in the development of novel antivirals and testing methods for antiviral drug resistance. This Special Issue aims to provide an update on the recent research progress in antiviral drug resistance and its testing as well as novel antiviral development from the perspectives of both basic and clinical/translational research and applications, which will inform the improvement in drug development, rapid diagnosis, and salvage therapy of refractory, drug-resistant viral infections.
Dr. Benjamin Liu
Dr. Jun Wang
Dr. David Hillyard
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antivirals
- viral hepatitis
- HIV
- Mpox
- influenza
- enterovirus
- chronic viral infections
- acute viral infections
- diagnosis
- antiviral drug resistance
- antiviral drug mutations
- antiviral drug development
- viral evolution
- treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
